Cover Story

Glucagon-like peptide 1 (GLP-1) is an important gut derived hormone that enables nutrient assimilation. There are several well-established actions of GLP-1, including stimulation of postprandial insulin secretion from β cells supporting development of GLP-1 medicines for type 2 diabetes (T2D), and reduction of appetite, enabling weight loss and approval of GLP-1-based medicines for the treatment of people with obesity. The expanding actions and improved efficacy of modern GLP-1 receptor agonists (GLP-1RAs) have led to increasing utilization of these medicines for people with T2D and obesity. Moreover, the safety of these medicines has been reinforced by data from cardiovascular outcome trials demonstrating reductions in rates of non-fatal myocardial infarction, non-fatal stroke, cardiovascular death and all-cause mortality.


Full text

 

 

All Articles

Thomas U. Greiner, Ara Koh, Eduard Peris, Mattias Bergentall, ... Fredrik Bäckhed

Junfeng Li, Yan Huang, Xinyu Yang, Yuli Cai, ... Zhongyuan Wen

Lionel Carneiro, Rocco Bernasconi, Adriano Bernini, Cendrine Repond, Luc Pellerin

Khang Nguyen, Jialing Tang, Sungji Cho, Fan Ying, ... Gary Sweeney

Camille Lefevre, Morgane M. Thibaut, Audrey Loumaye, Jean-Paul Thissen, ... Laure B. Bindels

Lin Zhu, Bridget Litts, Yu Wang, Jeffrey A. Rein, ... John M. Stafford

Ting Xiang, Liang Ma

Narendra Wajapeyee, Teresa Chiyanne Beamon, Romi Gupta

Seun Akindehin, Arkadiusz Liskiewicz, Daniela Liskiewicz, Miriam Bernecker, ... Timo D. Müller

Uwe Schlattner, Saadi Khochbin, Carlo Petosa

Hiroyuki Mori, Sydney K. Peterson, Rachel C. Simmermon, Katherine A. Overmyer, ... Ormond A. MacDougald

John D. Griffin, Ying Zhu, Andrew Reeves, Kimberly K. Buhman, Andrew S. Greenberg

Thibaut Desgeorges, Eva Galle, Jing Zhang, Ferdinand von Meyenn, Katrien De Bock

Charlotte Scholtes, Catherine Rosa Dufour, Emma Pleynet, Samaneh Kamyabiazar, ... Vincent Giguère

Debora S. Rocha, Antonio C. Manucci, Alexandre Bruni-Cardoso, Alicia J. Kowaltowski, Eloisa A. Vilas-Boas